ResearcherTongji HospitalActive in the last 2 years
Zhenxiong Zhang
Matched on OpenAlex author ID A5026205697. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 27
2022: 2 papers · 2023: 3 papers · 2024: none · 2025: none · 2026: 2 papers
Papers 7
- USP20-RAB8A signaling axis restricts pancreatic cancer progression by disrupting GLUT1 vesicular trafficking and inhibiting glucose uptake. Co-author DOI 10.1016/j.canlet.2026.218299↗
- Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and stabilizing BAG3. Co-author DOI 10.1038/s41418-026-01665-1↗
- Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.5210↗
- A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-022-01040-w↗
- An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1332626↗
- Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarcinoma: A propensity score-matching analys… Co-author DOI 10.1016/j.pan.2021.12.005↗
- LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. Co-author DOI 10.1186/s13046-022-02491-2↗
Closest collaborators
The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Renyi Qin · 6 shared papers, 2022–2026 · strength 1.07
- Paper Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and sta… DOI 10.1038/s41418-026-01665-1↗
- Paper USP20-RAB8A signaling axis restricts pancreatic cancer progression by disrupting GLUT1 vesicular trafficking and inhibi… DOI 10.1016/j.canlet.2026.218299↗
- Paper An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. DOI 10.3389/fimmu.2023.1332626↗
- Shutao Pan · 6 shared papers, 2022–2026 · strength 1.01
- Paper Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and sta… DOI 10.1038/s41418-026-01665-1↗
- Paper Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarci… DOI 10.1016/j.pan.2021.12.005↗
- Paper An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. DOI 10.3389/fimmu.2023.1332626↗
- Min Wang · 5 shared papers, 2022–2026 · strength 0.89
- Paper Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and sta… DOI 10.1038/s41418-026-01665-1↗
- Paper Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarci… DOI 10.1016/j.pan.2021.12.005↗
- Paper An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. DOI 10.3389/fimmu.2023.1332626↗
- Taoyuan Yin · 5 shared papers, 2022–2026 · strength 0.89
- Paper Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and sta… DOI 10.1038/s41418-026-01665-1↗
- Paper Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarci… DOI 10.1016/j.pan.2021.12.005↗
- Paper An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. DOI 10.3389/fimmu.2023.1332626↗
- Yongkang Shi · 4 shared papers, 2022–2026 · strength 0.78
- Paper Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and sta… DOI 10.1038/s41418-026-01665-1↗
- Paper USP20-RAB8A signaling axis restricts pancreatic cancer progression by disrupting GLUT1 vesicular trafficking and inhibi… DOI 10.1016/j.canlet.2026.218299↗
- Paper A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41418-022-01040-w↗
- Jun Gong · 4 shared papers, 2022–2026 · strength 0.71
- Paper Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and sta… DOI 10.1038/s41418-026-01665-1↗
- Paper An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. DOI 10.3389/fimmu.2023.1332626↗
- Paper A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41418-022-01040-w↗
- Min Zhou · 3 shared papers, 2023–2026 · strength 0.58
- Paper Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and sta… DOI 10.1038/s41418-026-01665-1↗
- Paper An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. DOI 10.3389/fimmu.2023.1332626↗
- Paper A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41418-022-01040-w↗
- Chunle Zhao · 3 shared papers, 2022–2026 · strength 0.55
- Paper Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and sta… DOI 10.1038/s41418-026-01665-1↗
- Paper A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41418-022-01040-w↗
- Paper LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to … DOI 10.1186/s13046-022-02491-2↗
- Yu Bai · 2 shared papers, 2026 · strength 0.49
- Paper Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and sta… DOI 10.1038/s41418-026-01665-1↗
- Paper USP20-RAB8A signaling axis restricts pancreatic cancer progression by disrupting GLUT1 vesicular trafficking and inhibi… DOI 10.1016/j.canlet.2026.218299↗
- Xingjun Guo · 2 shared papers, 2022–2023 · strength 0.30
- Renyi Qin · 1 shared paper, 2022 · strength 0.17
- Yuhui Liu · 1 shared paper, 2023 · strength 0.16
- Min Zhou · 1 shared paper, 2022 · strength 0.13
- Hongqin Ma · 1 shared paper, 2023 · strength 0.12
- Xuemin Chen · 1 shared paper, 2023 · strength 0.12
- Yichen Tang · 1 shared paper, 2023 · strength 0.12
- Jingdong Li · 1 shared paper, 2023 · strength 0.12
- Min Wang · 1 shared paper, 2023 · strength 0.12
- Yahui Liu · 1 shared paper, 2023 · strength 0.12
- Pei Lu · 1 shared paper, 2023 · strength 0.12
- Zheng Li · 1 shared paper, 2023 · strength 0.12
- Jun Liu · 1 shared paper, 2023 · strength 0.12
- Xianjun Yu · 1 shared paper, 2023 · strength 0.12
- Chen Liu · 1 shared paper, 2023 · strength 0.12
- Rong Liu · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.